ATE555795T1 - Verhinderung von magengeschwüren mit kohlenmonoxid - Google Patents

Verhinderung von magengeschwüren mit kohlenmonoxid

Info

Publication number
ATE555795T1
ATE555795T1 AT08788928T AT08788928T ATE555795T1 AT E555795 T1 ATE555795 T1 AT E555795T1 AT 08788928 T AT08788928 T AT 08788928T AT 08788928 T AT08788928 T AT 08788928T AT E555795 T1 ATE555795 T1 AT E555795T1
Authority
AT
Austria
Prior art keywords
carbon monoxide
stomach ulcer
preventing stomach
preventing
ulcer
Prior art date
Application number
AT08788928T
Other languages
English (en)
Inventor
Sandra Rodrigues
Joaeo Seixas
Bruno Guerreiro
Nuno Pereira
Carlos Romco
Werner Haas
Isabel Goncalves
Original Assignee
Alfama Investigacao E Desenvolvimento De Productos Farmaceuticos Lda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfama Investigacao E Desenvolvimento De Productos Farmaceuticos Lda filed Critical Alfama Investigacao E Desenvolvimento De Productos Farmaceuticos Lda
Application granted granted Critical
Publication of ATE555795T1 publication Critical patent/ATE555795T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08788928T 2007-07-24 2008-07-24 Verhinderung von magengeschwüren mit kohlenmonoxid ATE555795T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95165007P 2007-07-24 2007-07-24
PCT/IB2008/001945 WO2009013612A1 (en) 2007-07-24 2008-07-24 Prevention of gastric ulcery by carbon monoxide

Publications (1)

Publication Number Publication Date
ATE555795T1 true ATE555795T1 (de) 2012-05-15

Family

ID=40010478

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08788928T ATE555795T1 (de) 2007-07-24 2008-07-24 Verhinderung von magengeschwüren mit kohlenmonoxid

Country Status (5)

Country Link
US (3) US20110038955A1 (de)
EP (1) EP2182961B1 (de)
JP (1) JP5563452B2 (de)
AT (1) ATE555795T1 (de)
WO (1) WO2009013612A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7968605B2 (en) 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
AU2003208525B9 (en) 2002-02-04 2009-08-27 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Amend the invention title to read Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
GB2395432B (en) 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
EP1675459A1 (de) * 2003-08-04 2006-07-05 Hemocorm Limited Verwendung von borancarbonaten für die therapeutische abgabe von kohlenmonoxid
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
CN102791724A (zh) 2010-03-08 2012-11-21 苏黎世大学 用于医疗用途的一氧化碳释放铼化合物
US20130266668A1 (en) * 2010-12-01 2013-10-10 Virginia Commonwealth University Use of hemoglobin effectors to increase the bioavailability of therapeutic gases
EP2699242B1 (de) 2011-04-19 2017-11-01 Alfama, Inc. Kohlenmonoxidfreisetzende moleküle und ihre verwendungen
EP2734235B1 (de) 2011-07-21 2017-03-22 Alfama, Inc. Kohlenmonoxidfreisetzende rutheniummoleküle und ihre verwendungen
WO2015140337A1 (en) * 2014-03-21 2015-09-24 Universite Paris Est Creteil Val De Marne Fumarate-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
JP2018145248A (ja) * 2017-03-02 2018-09-20 国立大学法人京都大学 無限配位高分子（ＩＣＰｓ）を用いた一酸化炭素放出材料
JP7504088B2 (ja) * 2018-10-16 2024-06-21 ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド 医学的障害の治療のための一酸化炭素プロドラッグ
WO2022055991A1 (en) * 2020-09-08 2022-03-17 The Brigham And Women's Hospital, Inc. Therapeutic carbon monoxide formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065250A (en) * 1960-05-13 1962-11-20 Hercules Powder Co Ltd Nitrile-metal carbonyl complexes
US4569214A (en) * 1983-09-14 1986-02-11 Yang Yaw Kuen Push button security lock
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
AU2003208525B9 (en) * 2002-02-04 2009-08-27 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Amend the invention title to read Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
MXPA04012863A (es) * 2002-06-21 2005-03-31 Univ Pittsburgh Uso farmaceutico de oxido nitrico, heme oxigenasa-1 y productos de degradacion de heme.
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
GB0601394D0 (en) * 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
US20100196516A1 (en) * 2007-04-24 2010-08-05 ALFAMA-Investigacao e Desenvolvimento de produtos Farmaceuticos, Lda Treatment of infections by carbon monoxide

Also Published As

Publication number Publication date
US20140212514A1 (en) 2014-07-31
WO2009013612A1 (en) 2009-01-29
EP2182961A1 (de) 2010-05-12
JP2010534236A (ja) 2010-11-04
JP5563452B2 (ja) 2014-07-30
EP2182961B1 (de) 2012-05-02
US20170157168A1 (en) 2017-06-08
US20110038955A1 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
ATE555795T1 (de) Verhinderung von magengeschwüren mit kohlenmonoxid
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
IS8829A (is) Hvatar fyrir tvíþætta oxun á ammóníaki og kolmónoxíð með litla eða enga myndun á köfnunarefnisoxíði.
BR122013008865B8 (pt) adenovírus oncolítico de replicação competente
EA201070786A1 (ru) Бензофуропиримидиноны
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
EA201070237A1 (ru) Четвертичные опиоидные карбоксамиды
EA200700982A1 (ru) Производные хинолина и изохинолина, замещённые в 5-ом положении, способ их получения и их применение в качестве противовоспалительных средств
DE602007000824D1 (de) Projektor mit Polarisationskonverter
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
ATE554066T1 (de) Entzündungshemmende substituierte cyclobutendionverbindungen
DE602006019873D1 (de) Filmstrukturen mit verbesserter sauerstoffübertragung
CU23862B1 (es) Dispositivo para encender y operar quemadores en la gasificación de combustibles con carbono
DK1796698T3 (da) Stamme af lactobacillus acidophilus med analgetiske egenskaber i det gastrointestinale system
FR2897063B1 (fr) Polypeptides reconnus par des anticorps anti-trichinella, et leurs applications.
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
TW200716577A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
TR201102810T2 (tr) Tıbbi bir ürün ve tedavi
UY29594A1 (es) Derivados de benzotiazol-2-ona como inhibidores de lipasas y fosfolipasas
UA104274C2 (ru) Сероводородные производные нестероидных противовоспалительных лекарственных средств
NO20065460L (no) Anordning for pressing av krill og andre marine organismer
TR200903014A1 (tr) Oral yolla dağılan dimebolin bileşimleri.
BRPI0921091A2 (pt) Kit de formulações farmacêuticas caracterizado pela presença de oxigênio molecular.
RU2008129503A (ru) Бис{3-фенил-1-[2-(5-метил-1,3,4-тиадиазолил)]карбоксамидо-1,3-пропандионато}марганец, обладающий противоспалительной и анальгетической активностью
TR201007867T2 (tr) Uzatılmış salım sağlayan gliklazid tablet